Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Understanding the mechanisms driving the spread of subtype C HIV-1

(2020) Matthew J. Gartner et al.   EBioMedicine

Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic Benefits

(2019) Steven S. Forsythe et al.   HEALTH AFFAIRS

Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials

(2019) Peter B. Gilbert et al.   STATISTICS IN MEDICINE

Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment

(2019) Raabya Rossenkhan et al.   Viruses-Basel

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

(2019) Amarendra Pegu et al.   Cell Host & Microbe

Multiple roles for HIV broadly neutralizing antibodies

(2019) Barton F. Haynes et al.   Science Translational Medicine

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society— Lancet Commission

(2018) Linda-Gail Bekker et al.   LANCET

Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations

(2018) Chen Wang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development

(2018) Patrick M. Glassman et al.   Drug Metabolism and Pharmacokinetics

Recent progress in broadly neutralizing antibodies to HIV

(2018) Devin Sok et al.   NATURE IMMUNOLOGY

The expanding array of HIV broadly neutralizing antibodies

(2018) Laura E. McCoy   Retrovirology

Use of broadly neutralizing antibodies for HIV-1 prevention

(2017) Amarendra Pegu et al.   IMMUNOLOGICAL REVIEWS

Identification and specificity of broadly neutralizing antibodies against HIV

(2017) Laura E. McCoy et al.   IMMUNOLOGICAL REVIEWS

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

(2017) Yunda Huang et al.   mAbs

Recent advances in pre-exposure prophylaxis for HIV

(2017) Monica Desai et al.   BMJ-British Medical Journal

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

(2017) Kenneth H. Mayer et al.   PLOS MEDICINE

Recent advances in pre-exposure prophylaxis for HIV

(2017) Monica Desai et al.   BMJ-British Medical Journal

Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients

(2016) Julie H. Ishida et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

(2016) Cecilia Rademeyer et al.   PLoS Pathogens

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

(2015) J. E. Ledgerwood et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CATNAP: a tool to compile, analyze and tally neutralizing antibody panels

(2015) Hyejin Yoon et al.   NUCLEIC ACIDS RESEARCH

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

tmle: AnRPackage for Targeted Maximum Likelihood Estimation

(2015) Susan Gruber et al.   Journal of Statistical Software

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

(2014) A. Pegu et al.   Science Translational Medicine

A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1

(2013) Johannes S. Gach et al.   PLoS One

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

(2012) B. Moldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The origin and diversity of the HIV-1 pandemic

(2012) Joris Hemelaar   TRENDS IN MOLECULAR MEDICINE

Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells

(2011) Christopher A. Todd et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

(2010) T. Zhou et al.   SCIENCE

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity

(2008) A.B.H. Bakker et al.   VACCINE